Big result from @_ShankarSiva and the MASTERPLAN team. The detail for fellows: this is a randomized phase 2 whose primary endpoint was 12-month locoregional recurrence, so the survival gain is a striking secondary signal that a phase 3 should confirm. #ESMO26 #PancreaticCancer